Differentiation of autoimmune pancreatitis from suspected pancreatic cancer by fluorine-18 fluorodeoxyglucose positron emission tomography
暂无分享,去创建一个
Masumi Kadoya | Kazuhiro Oguchi | Takashi Muraki | Yayoi Ozaki | M. Kadoya | S. Kawa | H. Hamano | K. Kiyosawa | T. Muraki | Kendo Kiyosawa | Hideaki Hamano | Norikazu Arakura | Mitsuhiro Momose | Kazunobu Miyata | Takao Aizawa | Shigeyuki Kawa | K. Oguchi | N. Arakura | Y. Ozaki | M. Momose | T. Aizawa | K. Miyata | Yayoi Ozaki | Norikazu Arakura
[1] S. Kawa,et al. Prevalence and distribution of extrapancreatic lesions complicating autoimmune pancreatitis , 2007, Journal of Gastroenterology.
[2] S. Kawa,et al. Characteristic Pancreatic Duct Appearance in Autoimmune Chronic Pancreatitis: A Case Report and Review of the Japanese Literature , 1998, American Journal of Gastroenterology.
[3] Ludwig G. Strauss,et al. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients , 1996, European Journal of Nuclear Medicine.
[4] S. Kawa,et al. Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis , 2002, The Lancet.
[5] M. Schäfer,et al. Positron Emission Tomography/Computed Tomography Influences on the Management of Resectable Pancreatic Cancer and Its Cost-Effectiveness , 2005, Annals of surgery.
[6] Brady K. Huang,et al. Pancreatic pseudocyst observed on F-18 FDG PET imaging. , 2005, Clinical nuclear medicine.
[7] B. Diamond,et al. Autoimmune diseases , 2000, Bone Marrow Transplantation.
[8] H. Sakahara,et al. Delayed 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas , 2000, Cancer.
[9] H. Sakai,et al. Autoimmune Pancreatitis as a New Clinical Entity (Three Cases of Autoimmune Pancreatitis with Effective Steroid Therapy) , 1997, Digestive Diseases and Sciences.
[10] G. Glatting,et al. F-18 Fluorodeoxyglucose (FDG) and C-Reactive Protein (CRP). , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[11] 濱野 英明. High serum IgG4 concentrations in patients with sclerosing pancreatitis , 2002 .
[12] T. Saga,et al. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) —Usefulness and limitations in “clinical reality”— , 2003, Annals of nuclear medicine.
[13] S. Kawa,et al. ERCP features in 27 patients with autoimmune pancreatitis. , 2002, Gastrointestinal endoscopy.
[14] F. Chierichetti,et al. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: A prospective study , 2007, Journal of Gastrointestinal Surgery.
[15] John L. Cameron,et al. Pancreaticoduodenectomy (Whipple Resections) in Patients Without Malignancy: Are They All `Chronic Pancreatitis'? , 2003, The American journal of surgical pathology.
[16] S. Hauptmann,et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. , 1994, Radiology.
[17] E. Nitzsche,et al. Evaluation of positron emission tomography with 2‐[18F]fluoro‐2‐deoxy‐D‐glucose for the differentiation of chronic pancreatitis and pancreatic cancer , 1999, The British journal of surgery.
[18] O. Sabri,et al. Fluorine-18 fluorodeoxyglucose positron mission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases , 1997, European Journal of Nuclear Medicine.
[19] T Ido,et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] T. Shimosegawa,et al. Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal , 2006, Journal of Gastroenterology.
[21] P. Shreve. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease , 1998, European Journal of Nuclear Medicine.
[22] S. Kawa,et al. CHAPTER 56 – Pancreatitis , 2006 .
[23] K. Shiratori,et al. Chronic pancreatitis caused by an autoimmune abnormality , 1995, Digestive Diseases and Sciences.
[24] Higashi,et al. Autoimmune pancreatitis with F-18 fluoro-2-deoxy-D-glucose PET findings , 1999, Clinical nuclear medicine.
[25] M. Kadoya,et al. Hilar and Pancreatic Gallium-67 Accumulation is Characteristic Feature of Autoimmune Pancreatitis , 2003, Pancreas.
[26] H. Sakahara,et al. FDG-PET of autoimmune-related pancreatitis: preliminary results , 2000, European Journal of Nuclear Medicine.
[27] W. Chapman,et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] M. Nagino,et al. Intense PET signal in the degenerative necrosis superimposed on chronic pancreatitis. , 2005, Pancreas.
[29] J. Drebin. Positron Emission Tomography/Computed Tomography Influences on the Management of Resectable Pancreatic Cancer and Its Cost-effectiveness , 2006 .
[30] N. Rose. Autoimmune diseases. , 1981, Scientific American.
[31] W. Oyen,et al. FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[32] Y. Yonekura,et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. , 1995, Radiology.
[33] A. Luxen,et al. Whole-body tumor imaging using PET and 2-18F-fluoro-L-tyrosine: preliminary evaluation and comparison with 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.